Title : Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Pub. Date : 2012 Jan 15

PMID : 22048237






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens
2 PURPOSE: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens